- Home
- EVRG vs GH Comparison
EVRG vs GH Comparison
Compare EVRG & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVRG | GH |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 17.3B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EVRG | GH |
|---|---|---|
| Price | $87.95 | $168.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 19 |
| Target Price | $87.38 | ★ $119.79 |
| AVG Volume (30 Days) | 1.9M | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $5,961,600,000.00 | $982,021,000.00 |
| Revenue This Year | $6.52 | $33.30 |
| Revenue Next Year | $7.12 | $28.27 |
| P/E Ratio | $137.65 | ★ N/A |
| Revenue Growth | 1.95 | ★ 32.88 |
| 52 Week Low | $67.32 | $40.36 |
| 52 Week High | $88.15 | $172.61 |
Technical Indicators
Market Signals| Indicator | EVRG | GH |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 78.43 |
| Support Level | $80.34 | $94.02 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.33 | 6.98 |
| MACD | 0.37 | 2.85 |
| Stochastic Oscillator | 99.19 | 91.92 |
Price Performance
Historical ComparisonAbout EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission. The utility has a combined rate base of more than $20 billion, about half in Kansas and the rest split between Missouri and interstate transmission. Evergy is one of the largest wind energy suppliers in the US.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.